Latest Adalimumab Stories
Tokyo, Sept 11, 2012 - (JCN Newswire) - Eisai Co., Ltd.
People suffering from ulcerative colitis may be getting some new relief due to a decision by the Food and Drug Administration (FDA) to open a new drug to help alleviate symptoms.
New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade).
Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease.
Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20.
Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by €2,595,557 per 272 patients over 3 years (95 percentile range -€2,983,760 to -€2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs).
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.